142 related articles for article (PubMed ID: 35943644)
21. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
22. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
Jiménez B; Trigo JM; Pajares BI; Sáez MI; Quero C; Navarro V; Llácer C; Medina L; Rueda A; Alba E
Oral Oncol; 2013 Feb; 49(2):182-5. PubMed ID: 23026069
[TBL] [Abstract][Full Text] [Related]
24. Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Cohen MH; Chen H; Shord S; Fuchs C; He K; Zhao H; Sickafuse S; Keegan P; Pazdur R
Oncologist; 2013; 18(4):460-6. PubMed ID: 23576486
[TBL] [Abstract][Full Text] [Related]
25. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma.
Okada T; Okamoto I; Sato H; Ito T; Miyake K; Tsukahara K
In Vivo; 2021; 35(2):1253-1259. PubMed ID: 33622928
[TBL] [Abstract][Full Text] [Related]
27. Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Carinato H; Burgy M; Ferry R; Fischbach C; Kalish M; Guihard S; Brahimi Y; Flesch H; Bronner G; Schultz P; Frasie V; Thiéry A; Demarchi M; Petit T; Jung AC; Wagner P; Coliat P; Borel C
Front Oncol; 2021; 11():714551. PubMed ID: 34778031
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
29. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
30. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
31. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
32. Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Meirovitz A; Bergerson S; Hirshoren N; Weinberger JM; Bersudski E; Daniel S; Sheva K; Perez CA
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1479. PubMed ID: 34184405
[TBL] [Abstract][Full Text] [Related]
33. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
34. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.
Rangaraju RR; Sharma JB; Dewan AK; Anand AK; Sheh R; Jena A; Chaturvedi AK
Indian J Cancer; 2012; 49(1):1-5. PubMed ID: 22842160
[TBL] [Abstract][Full Text] [Related]
35. Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer.
Hoch MA; Cousins K; Nartey R; Riley K; Hartranft M
J Oncol Pharm Pract; 2018 Oct; 24(7):553-554. PubMed ID: 28764598
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
Péron J; Ceruse P; Lavergne E; Buiret G; Pham BN; Chabaud S; Favier B; Girodet D; Zrounba P; Ramade A; Fayette J
Anticancer Drugs; 2012 Oct; 23(9):996-1001. PubMed ID: 22643048
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Dunn LA; Fury MG; Xiao H; Baxi SS; Sherman EJ; Korte S; Pfister C; Haque S; Katabi N; Ho AL; Pfister DG
Ann Oncol; 2017 Oct; 28(10):2533-2538. PubMed ID: 28961834
[TBL] [Abstract][Full Text] [Related]
38. Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study.
Buxó E; Sosa A; Reig O; Victoria I; Caballero M; Grau JJ; Garcia-Morillo M
Ann Otol Rhinol Laryngol; 2018 Jul; 127(7):456-462. PubMed ID: 29852745
[TBL] [Abstract][Full Text] [Related]
39. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
[TBL] [Abstract][Full Text] [Related]
40. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma.
Yanamoto S; Umeda M; Kioi M; Kirita T; Yamashita T; Hiratsuka H; Yokoo S; Tanzawa H; Uzawa N; Shibahara T; Ota Y; Kurita H; Okura M; Hamakawa H; Kusukawa J; Tohnai I
Cancer Chemother Pharmacol; 2018 Mar; 81(3):549-554. PubMed ID: 29383483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
